

Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
11.1	2025/11/13	20451-00028	2025/05/09
			Date of first issue: 2014/10/09

1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Raltegravir Pediatric Granules Formulation

Supplier's company name, address and phone number

Company name of supplier : MSD

Address : Kumagaya, Saitama Prefecture , Xicheng 810 MSD Co., Ltd.
Menuuma factory

Telephone : 048-588-8411

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION**GHS classification of chemical product**

Serious eye damage/eye irritation : Category 1

Reproductive toxicity : Category 2

Specific target organ toxicity - single exposure : Category 3

Short-term (acute) aquatic hazard : Category 3

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H318 Causes serious eye damage.
H335 May cause respiratory irritation.
H361d Suspected of damaging the unborn child.
H402 Harmful to aquatic life.

Precautionary statements : **Prevention:**

Raltegravir Pediatric Granules Formulation

Version 11.1	Revision Date: 2025/11/13	SDS Number: 20451-00028	Date of last issue: 2025/05/09 Date of first issue: 2014/10/09
-----------------	------------------------------	----------------------------	---

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P261 Avoid breathing dust.
P271 Use only outdoors or in a well-ventilated area.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Important symptoms and out- : Contact with dust can cause mechanical irritation or drying of
lines of the emergency as- the skin.
sumed May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Raltegravir	871038-72-1	>= 20 - < 25	
Cellulose	9004-34-6	>= 20 - < 30	
Magnesium stearate	557-04-0	>= 1 - < 10	2-611
Ammonium hydroxide	1336-21-6	>= 0.1 - < 1	1-314

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

Raltegravir Pediatric Granules Formulation

Version 11.1	Revision Date: 2025/11/13	SDS Number: 20451-00028	Date of last issue: 2025/05/09 Date of first issue: 2014/10/09
-----------------	------------------------------	----------------------------	---

If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention immediately.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Causes serious eye damage. May cause respiratory irritation. Suspected of damaging the unborn child. Contact with dust can cause mechanical irritation or drying of the skin.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire-fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Nitrogen oxides (NO _x) Fluorine compounds Metal oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Raltegravir Pediatric Granules Formulation

Version 11.1	Revision Date: 2025/11/13	SDS Number: 20451-00028	Date of last issue: 2025/05/09 Date of first issue: 2014/10/09
-----------------	------------------------------	----------------------------	---

6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air.
Add excess liquid to allow the material to enter into solution.
Soak up with inert absorbent material.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE**Handling**

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Avoid breathing dust.
Do not swallow.
Do not get in eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.

Raltegravir Pediatric Granules Formulation

Version 11.1	Revision Date: 2025/11/13	SDS Number: 20451-00028	Date of last issue: 2025/05/09 Date of first issue: 2014/10/09
-----------------	------------------------------	----------------------------	---

Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact : Oxidizing agents
Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Storage

Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Keep in a cool, well-ventilated place.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Packaging material : Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Threshold limit value and permissible exposure limits for each component in the work environment

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Concentration standard / Permissible concentration	Basis
Raltegravir	871038-72-1	TWA	1000 (µg/m ³) (OEB 1)	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH
Ammonium hydroxide	1336-21-6	TWA	25 ppm (Ammonia)	ACGIH
		STEL	35 ppm (Ammonia)	ACGIH

Raltegravir Pediatric Granules Formulation

Version 11.1	Revision Date: 2025/11/13	SDS Number: 20451-00028	Date of last issue: 2025/05/09 Date of first issue: 2014/10/09
-----------------	------------------------------	----------------------------	---

Engineering measures : Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Eye protection

: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection

: Work uniform or laboratory coat.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state : powder

Colour : off-white

Odour : odourless

Odour Threshold : No data available

Melting point/freezing point : No data available

Boiling point, initial boiling point and boiling range : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Lower explosion limit and upper explosion limit / flammability limit

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : No data available

Decomposition temperature : No data available

pH : No data available

Raltegravir Pediatric Granules Formulation

Version 11.1	Revision Date: 2025/11/13	SDS Number: 20451-00028	Date of last issue: 2025/05/09 Date of first issue: 2014/10/09
-----------------	------------------------------	----------------------------	---

Evaporation rate	:	No data available
Auto-ignition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Vapour pressure	:	No data available
Density and / or relative density		
Relative density	:	No data available
Relative vapour density	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	No data available

10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/05/09
11.1	2025/11/13	20451-00028	Date of first issue: 2014/10/09

Acute toxicity

Not classified based on available information.

Components:**Raltegravir:**

Acute oral toxicity : LD50 (Mouse, male and female): > 2,000 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Ammonium hydroxide:

Acute oral toxicity : LD50 (Rat): 350 mg/kg

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

Skin corrosion/irritation

Not classified based on available information.

Components:**Raltegravir:**

Species : Rabbit
Result : No skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Ammonium hydroxide:

Species : Rabbit
Result : Corrosive after 3 minutes to 1 hour of exposure
Remarks : Based on national or regional regulation.

Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/05/09
11.1	2025/11/13	20451-00028	Date of first issue: 2014/10/09

Serious eye damage/eye irritation

Causes serious eye damage.

Components:**Raltegravir:**

Species	:	Bovine cornea
Result	:	Severe irritation

Magnesium stearate:

Species	:	Rabbit
Result	:	No eye irritation
Remarks	:	Based on data from similar materials

Ammonium hydroxide:

Result	:	Irreversible effects on the eye
Remarks	:	Based on skin corrosivity.

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Raltegravir:**

Test Type	:	Local lymph node assay (LLNA)
Species	:	Mouse
Result	:	negative

Magnesium stearate:

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative
Remarks	:	Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:**Raltegravir:**

Genotoxicity in vitro	:	Test Type: reverse mutation assay
		Result: negative

Test Type: Alkaline elution assay

Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
11.1	2025/11/13	20451-00028	2025/05/09
			Date of first issue: 2014/10/09

Test system: rat hepatocytes
Result: negative

Test Type: Chromosomal aberration
Method: OECD Test Guideline 473
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Test Type: Chromosomal aberration
Method: OECD Test Guideline 475
Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Ammonium hydroxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Carcinogenicity

Not classified based on available information.

Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/05/09
11.1	2025/11/13	20451-00028	Date of first issue: 2014/10/09

Components:**Raltegravir:**

Species	:	Mouse, male and female
Exposure time	:	104 weeks
Result	:	negative

Cellulose:

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	72 weeks
Result	:	negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:**Raltegravir:**

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat, male and female Application Route: Oral General Toxicity - Parent: NOAEL: 600 mg/kg body weight Result: negative
----------------------	---	---

Effects on foetal development	:	Species: Rat Application Route: Oral General Toxicity Maternal: NOAEL: $\geq$ 600 mg/kg body weight Teratogenicity: LOAEL F1: 300 mg/kg body weight Symptoms: Skeletal malformations Result: positive
-------------------------------	---	--

	:	Species: Rabbit General Toxicity Maternal: NOAEL: $\geq$ 1,000 mg/kg body weight Teratogenicity: NOAEL: $\geq$ 1,000 mg/kg body weight Result: negative
--	---	--

Reproductive toxicity - Assessment	:	Some evidence of adverse effects on development, based on animal experiments.
------------------------------------	---	---

Cellulose:

Effects on fertility	:	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
----------------------	---	---

Effects on foetal development	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative
-------------------------------	---	--

Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/05/09
11.1	2025/11/13	20451-00028	Date of first issue: 2014/10/09

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure

May cause respiratory irritation.

Components:**Raltegravir:**

Exposure routes : Inhalation
Target Organs : Respiratory Tract
Assessment : May cause respiratory irritation.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity**Components:****Raltegravir:**

Species : Dog
NOAEL : 90 mg/kg
Application Route : Oral
Exposure time : 371 d
Symptoms : Vomiting

Species : Rat
NOAEL : 30 mg/kg
LOAEL : 120 mg/kg
Application Route : Oral
Exposure time : 189 d
Target Organs : Stomach

Species : Mouse
NOAEL : 50 mg/kg
LOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Target Organs : Stomach

Species : Rat

Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/05/09
11.1	2025/11/13	20451-00028	Date of first issue: 2014/10/09

NOAEL	:	50 mg/kg
LOAEL	:	200 mg/kg
Application Route	:	Oral
Exposure time	:	8 Weeks
Target Organs	:	Stomach

Cellulose:

Species	:	Rat
NOAEL	:	>= 9,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

Magnesium stearate:

Species	:	Rat
NOAEL	:	> 100 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Remarks	:	Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Raltegravir:**

Ingestion	:	Symptoms: Nausea, Diarrhoea, Headache, Fever, Rash, Skin irritation
-----------	---	---

12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Raltegravir:**

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 LC50 (Cyprinodon variegatus (sheepshead minnow)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): 66 mg/l Exposure time: 96 h

Raltegravir Pediatric Granules Formulation

Version 11.1	Revision Date: 2025/11/13	SDS Number: 20451-00028	Date of last issue: 2025/05/09 Date of first issue: 2014/10/09
-----------------	------------------------------	----------------------------	---

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 3.8 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 9.3 mg/l
Exposure time: 33 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 9.5 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition

Method: OECD Test Guideline 209

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Method: Directive 67/548/EEC, Annex V, C.2.
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l

Raltegravir Pediatric Granules Formulation

Version 11.1	Revision Date: 2025/11/13	SDS Number: 20451-00028	Date of last issue: 2025/05/09 Date of first issue: 2014/10/09
-----------------	------------------------------	----------------------------	---

Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (*Pseudomonas putida*): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Ammonium hydroxide:

Toxicity to fish : LC50 (*Oncorhynchus mykiss* (rainbow trout)): 0.89 mg/l
Exposure time: 96 h
Test substance: Neutralised product

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): 101 mg/l
Exposure time: 48 h

M-Factor (Acute aquatic toxicity) : 1

Toxicity to fish (Chronic toxicity) : NOEC (*Oncorhynchus mykiss* (rainbow trout)): 0.0135 mg/l
Exposure time: 73 d
Test substance: Neutralised product

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (*Daphnia magna* (Water flea)): 0.961 mg/l
Exposure time: 21 d
Remarks: Based on data from similar materials

Persistence and degradability**Components:****Raltegravir:**

Biodegradability : Result: rapidly degradable
Biodegradation: 50 %
Exposure time: 9 d
Method: OECD Test Guideline 302B

Stability in water : Hydrolysis: < 10 % (5 d)
Method: OECD Test Guideline 111

Cellulose:

Biodegradability : Result: Readily biodegradable.

Magnesium stearate:

Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/05/09
11.1	2025/11/13	20451-00028	Date of first issue: 2014/10/09

Bioaccumulative potential**Components:****Raltegravir:**

Partition coefficient: n-octanol/water : log Pow: -0.328

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

No data available

Hazardous to the ozone layer

Not applicable

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues	:	Dispose of in accordance with local regulations. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

IATA-DGR

Not regulated as a dangerous good

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable

Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/05/09
11.1	2025/11/13	20451-00028	Date of first issue: 2014/10/09

ger aircraft)

IMDG-Code

Not regulated as a dangerous good

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
EmS Code	:	Not applicable
Marine pollutant	:	Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

Refer to section 15 for specific national regulation.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION**Related Regulations****Fire Service Law**

Not applicable to dangerous materials / designated flammables.

Chemical Substance Control Law

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

Industrial Safety and Health Law**Harmful Substances Prohibited from Manufacture**

Not applicable

Harmful Substances Required Permission for Manufacture

Not applicable

Substances Prevented From Impairment of Health

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Not applicable

Substances Subject to be Notified Names

Law Article 57-2 (Ministerial Order Article 34-2 Appended Table 2)

Chemical name	Concentration (%)	Remarks
Magnesium stearate	≥ 1 - < 10	-
Ammonia	≥ 0.1 - < 1	-

Raltegravir Pediatric Granules Formulation

Version 11.1	Revision Date: 2025/11/13	SDS Number: 20451-00028	Date of last issue: 2025/05/09 Date of first issue: 2014/10/09
-----------------	------------------------------	----------------------------	---

Substances Subject to be Indicated Names

Law Article 57 (Ministerial Order Article 30 Appended Table 2)

Chemical name	Remarks
Magnesium stearate	-

Skin and Eye Damage Substances (ISHL MO Art. 594-2)

Not applicable

Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)

Not applicable

Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

Ordinance on Prevention of Lead Poisoning

Not applicable

Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

Ordinance on Prevention of Organic Solvent Poisoning

Not applicable

Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)

Not applicable

Poisonous and Deleterious Substances Control Law

Not applicable

Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof

Not applicable

High Pressure Gas Safety Act

Not applicable

Explosive Control Law

Not applicable

Vessel Safety Law

Not regulated as a dangerous good

Aviation Law

Not regulated as a dangerous good

Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Not classified as marine pollutant

Narcotics and Psychotropics Control Act

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

Raltegravir Pediatric Granules Formulation

Version 11.1	Revision Date: 2025/11/13	SDS Number: 20451-00028	Date of last issue: 2025/05/09 Date of first issue: 2014/10/09
-----------------	------------------------------	----------------------------	---

Waste Disposal and Public Cleansing Law

Industrial waste

The components of this product are reported in the following inventories:

AICS	: not determined
CA. DSL	: not determined
IECSC	: not determined

16. OTHER INFORMATION

In this SDS, if the concentration of substances subject to notification under the Industrial Safety and Health Law is indicated as a range, it includes cases where it is a trade secret.

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

ACGIH / STEL : Short-term exposure limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonised System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organisation; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardisation; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MERCOSUR - The Agreement for the Facilitation of the Transport of Dangerous Goods; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organisation for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authori-

Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/05/09
11.1	2025/11/13	20451-00028	Date of first issue: 2014/10/09

sation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN